Drugs

Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus: An Update
pp. 433-445(13)
Authors: Marcel M.C. Hovens; Jouke T. Tamsma; Edith D. Beishuizen; Menno V. Huisman

New Treatment Modalities for Vitiligo: Focus on Topical Immunomodulators
pp. 447-459(13)
Authors: Kresimir Kostovic; Aida Pasic

Adverse Effects and Drug Interactions of Antithrombotic Agents Used in Prevention of Ischaemic Stroke
pp. 461-471(11)
Author: Jesse Weinberger

An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis: Focus on Tumour Necrosis Factor- Antagonists
pp. 473-496(24)
Authors: Nick J. Bansback; Dean A. Regier; Roberta Ara; Alan Brennan; Kamran Shojania; John M. Esdaile; Aslam H. Anis; Carlo A. Marra

Management of Sight-Threatening Uveitis: New Therapeutic Options
pp. 497-519(23)
Authors: Matthias D. Becker; Justine R. Smith; Regina Max; Christoph Fiehn

Peginterferon -2a (40KD) Plus Ribavirin: A Review of its Use in the Management of Patients with Chronic Hepatitis C and Persistently ‘Normal’ ALT Levels
pp. 521-536(16)
Authors: Gillian M. Keating; Greg L. Plosker

Candesartan Cilexetil: A Review of its Use In the Management of Chronic Heart Failure
pp. 537-558(22)
Authors: Caroline Fenton; Lesley J. Scott

Paricalcitol: A Review of its Use in the Management of Secondary Hyperparathyroidism
pp. 559-576(18)
Authors: Dean M. Robinson; Lesley J. Scott

5-Lipoxygenase as a Putative Mechanism of NSAID-Related Psychiatric Adverse Events
pp. 577-577(1)
Author: Adis International Limited